SequelSEC

Indaptus Therapeutics, Inc. INDP

Pharmaceutical Preparations · CIK 0001857044 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
-$19.83M
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

Indaptus Therapeutics, Inc. (INDP) reported net income of -$20.85M for the fiscal year ended 2025-12-31. This page shows 6 annual periods of income statement, balance sheet and cash flow figures normalized from Indaptus Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Indaptus Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$19.83M-$15.37M-$16.38M-$14.91M-$7.73M-$3.60M
Net income-$20.85M-$15.02M-$15.42M-$14.32M-$7.71M-$3.58M
Research & development$9.34M$7.25M$7.62M$6.32M$2.52M$2.66M
Weighted-average diluted sharesUnavailableUnavailableshares 8.40Mshares 8.26MUnavailableUnavailable
Pretax income-$20.85M-$15.02MUnavailableUnavailableUnavailableUnavailable
Income tax expense$1.72K$1.70K$2.45K$30$1.65K$800
Diluted EPS$-21.58$-44.96$-1.83$-1.73UnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$10.49M$8.11M$8.76M$8.59M$5.21M$944.25K
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Indaptus Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Cash & equivalents$8.51M$5.79M$13.36M$9.63M$39.13M$1.64M
Total assets$9.31M$7.34M$14.92M$28.06M$40.58M$1.78M
Current assets$9.31M$6.62M$14.00M$27.24M$40.39M$1.73M
Total liabilities$6.16M$3.39M$2.85M$3.43M$4.68M$2.02M
Current liabilities$6.16M$3.39M$2.77M$3.43M$4.60M$2.02M
Total equity incl. NCI$3.15M$3.94M$12.08M$24.63M$35.90M-$237.70K
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$544.06K$870.23K$806.00K$1.38M$2.54M$155.96K

Cash flow

Indaptus Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Operating cash flow-$14.82M-$12.32M-$13.41M-$13.08M-$11.29M-$3.32M
Capital expendituresUnavailableUnavailableUnavailableUnavailable$3.85KUnavailable
Investing cash flowUnavailableUnavailable$17.14M-$16.43M$447.75KUnavailable
Financing cash flow$17.54M$4.75MUnavailableUnavailable$48.34M$1.16M
Net change in cashUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Stock-based compensation$1.36M$2.31M$2.97M$2.96M$1.51M$139.96K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

Indaptus Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Free cash flowUnavailableUnavailableUnavailableUnavailable-$11.29MUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio1.51x1.95x5.05x7.94x8.77x0.86x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open INDP in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-K · Filed 2026-03-17View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-13View SEC filing
10-Q · Filed 2025-05-14View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.